Background: There are no data to assess the value associated with a treat-to-target (T2T) strategy based on tight control of mild–moderate ulcerative colitis (UC). Aim: To assess the cost-effectiveness of a T2T approach based on the normalisation of clinical signs and faecal calprotectin (FC). Methods: A decision analytical Markov model was developed to compare T2T algorithm combining clinical symptoms and FC levels to define treatment response and the possible switch to the next treatment line (T2T-FC), and the reference strategy based only on symptoms. The model included five treatment lines and was conducted from the Italian national health service (NHS) perspective using a 3-year time horizon. The model calculated the incremental cost-effectiveness ratio as € per relapse avoided. Deterministic and probabilistic sensitivity analyses were conducted. Results: The cost-effectiveness analysis produced an increased time spent by a patient in clinical remission and FC ≤ 100 level (+0.177 years; about 2 months) and a decreasing number of relapses (−0.1937; −20.9%) per patient using a T2T-FC approach compared to only symptoms. Furthermore, the T2T-FC was associated with higher cost (+€1795). The ICER estimated was €9263 per relapse avoided. These results were confirmed by sensitivity analyses. Conclusions: T2T-FC approach resulted in a higher benefit for mild–moderate UC patients in terms of time in remission and incidence of relapse but was associated with higher costs. Clinical trials and real-world clinical studies are needed to provide additional data on the cost–benefit of this approach.

Cortesi, P., Fiorino, G., Peyrin-Biroulet, L., Mantovani, L., Jairath, V., Paridaens, K., et al. (2023). Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild–moderate ulcerative colitis. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 57(5 (March 2023)), 486-495 [10.1111/apt.17261].

Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild–moderate ulcerative colitis

Cortesi P. A.
Primo
;
Mantovani L. G.;
2023

Abstract

Background: There are no data to assess the value associated with a treat-to-target (T2T) strategy based on tight control of mild–moderate ulcerative colitis (UC). Aim: To assess the cost-effectiveness of a T2T approach based on the normalisation of clinical signs and faecal calprotectin (FC). Methods: A decision analytical Markov model was developed to compare T2T algorithm combining clinical symptoms and FC levels to define treatment response and the possible switch to the next treatment line (T2T-FC), and the reference strategy based only on symptoms. The model included five treatment lines and was conducted from the Italian national health service (NHS) perspective using a 3-year time horizon. The model calculated the incremental cost-effectiveness ratio as € per relapse avoided. Deterministic and probabilistic sensitivity analyses were conducted. Results: The cost-effectiveness analysis produced an increased time spent by a patient in clinical remission and FC ≤ 100 level (+0.177 years; about 2 months) and a decreasing number of relapses (−0.1937; −20.9%) per patient using a T2T-FC approach compared to only symptoms. Furthermore, the T2T-FC was associated with higher cost (+€1795). The ICER estimated was €9263 per relapse avoided. These results were confirmed by sensitivity analyses. Conclusions: T2T-FC approach resulted in a higher benefit for mild–moderate UC patients in terms of time in remission and incidence of relapse but was associated with higher costs. Clinical trials and real-world clinical studies are needed to provide additional data on the cost–benefit of this approach.
Articolo in rivista - Articolo scientifico
calprotectin; cost-effectiveness; mild–moderate ulcerative colitis; monitoring;
English
15-nov-2022
2023
57
5 (March 2023)
486
495
reserved
Cortesi, P., Fiorino, G., Peyrin-Biroulet, L., Mantovani, L., Jairath, V., Paridaens, K., et al. (2023). Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild–moderate ulcerative colitis. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 57(5 (March 2023)), 486-495 [10.1111/apt.17261].
File in questo prodotto:
File Dimensione Formato  
Cortesi-2022-Aliment Pharmacol Ther-VoR.pdf

Solo gestori archivio

Descrizione: Original Article
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Tutti i diritti riservati
Dimensione 771.57 kB
Formato Adobe PDF
771.57 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/402344
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 5
Social impact